Monday, October 3, 2022


Biotechnology News Magazine

Adaptate Biotherapeutics Raises $18 million in Series A2 Funding

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

April 19, 2021

Adaptate Biotherapeutics, a company focussed on developing antibody-based therapeutics for modulation of gamma delta T cells, today announced that its existing investors, Abingworth and Takeda Pharmaceutical Company Limited (Takeda) have together made a further equity investment of $18 million (circa. £13 million).

This funding brings the total raised since Adaptate’s inception in late 2019 to $34 million (circa. £25 million).

The investment results from the rapid progress made by the Company over the past 18 months. The funds will be used to accelerate the progression of Adaptate’s lead therapeutic antibody programme towards the clinic and to expand its internal product pipeline. The Company’s growing portfolio includes both monoclonal and bispecific antibodies which target gamma delta T cells, a unique class of lymphocytes that bridge innate and adaptive immunity. The Company’s most advanced programmes are focussed on treatments for cancer patients with solid tumours. Adaptate’s antibodies selectively target gamma delta T cells, thereby offering the opportunity for superior efficacy and safety compared to conventional immunomodulatory therapies such as pan T cell activators.

The financing will also support the Company’s expansion, including further recruitment and increased laboratory and office space. This expansion exemplifies Adaptate’s rapid growth plans and the additional capacity will play a key role in further boosting research and development activities.

Dr. Natalie Mount, CEO of Adaptate Biotherapeutics, said: “The funding is a great vote of confidence from our existing investors and testimony to the hard work and rapid progress we have made in the novel field of gamma delta T cell targeting antibodies. We are excited to continue this growth path and to progress our unique therapeutic antibodies towards clinical trials where we look forward to them making an impact on the treatments available to cancer patients.”

Tim Haines, Chairman & Managing Partner, Abingworth , commented: “We have been impressed with the potential of Adaptate’s therapeutic antibody technology and the significant progress to date.. We are delighted to invest further, to enable the team to accelerate its very promising portfolio towards the clinic.”

Loic Vincent, Head, Oncology Drug Discovery Unit, Takeda, added: “Takeda’s ongoing investment in Adaptate aligns closely with our pursuit of potentially life-changing treatments for cancer patients through novel immuno-oncology approaches. We look forward to continuing to work together on the potential of gamma delta T cell targeted therapies to achieve this goal.”

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine